AHA GUIDELINES Bundle (free trial)

Stable Ischemic Heart Disease

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/102913

Contents of this Issue

Navigation

Page 37 of 45

36 Follow-up Clinical Evaluation, Echocardiography During Routine, Periodic Follow-Up Î Patients with SIHD should receive periodic follow-up, at least annually, that includes all of the following: (I-C) • Assessment of symptoms and clinical function • Surveillance for complications of SIHD, including heart failure and arrhythmias • Monitoring of cardiac risk factors • Assessment of the adequacy of and adherence to recommended lifestyle changes and medical therapy ÎAssessment of LVEF and segmental wall motion by echocardiography or radionuclide imaging is recommended in patients with new or worsening heart failure or evidence of intervening MI by history or ECG. (I-C) Î Periodic screening for important comorbidities that are prevalent in patients with SIHD, including diabetes mellitus, depression, and CKD, might be reasonable. (IIb-C) Î A resting 12-lead ECG at 1-year or longer intervals between studies in patients with stable symptoms might be reasonable. (IIb-C) Î Measurement of LV function with a technology such as echocardiography or radionuclide imaging is NOT recommended for routine periodic reassessment of patients who have not had a change in clinical status or who are at low risk of adverse cardiovascular events. (III-C: No Benefit) Noninvasive Testing in Known SIHD Follow-Up Noninvasive Testing in Patients With Known SIHD: New, Recurrent, or Worsening Symptoms Not Consistent With Unstable Angina Patients Able to Exercise Î Standard exercise ECG testing is recommended in patients with known SIHD who have new or worsening symptoms not consistent with UA and who have: (I-B) • at least moderate physical functioning and no disabling comorbidity and • an interpretable ECG Î Exercise with nuclear MPI or echocardiography is recommended in patients with known SIHD who have new or worsening symptoms not consistent with UA and who have: (I-B) • at least moderate physical functioning or no disabling comorbidity but • an uninterpretable ECG

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Stable Ischemic Heart Disease